Status:

COMPLETED

The Calmer Project

Lead Sponsor:

Children's & Women's Health Centre of British Columbia

Conditions:

Acute Pain

Eligibility:

All Genders

27-36 years

Phase:

NA

Brief Summary

The purpose of this study is to see if the Calmer is more effective at managing acute pain in preterm infants in the neonatal intensive care than the current standard of care in the unit. Hypothesis:...

Detailed Description

60 infants will be randomized to either receive the standard of care or the Calmer during a routine blood collection.

Eligibility Criteria

Inclusion

  • Stable infants admitted to the Neonatal Intensive Care Unit at Children's and Women's Health Centre of British Columbia (C\&W)
  • Preterm infants born at 27 to 36+6 completed weeks gestational age (GA) will be included
  • GA is determined on the basis of the first day of the last menstrual period, early gestation ultrasonogram (in most cases) or best estimate based on neonatal examination
  • Mothers must speak enough English to provide consent

Exclusion

  • Infants who have congenital anomalies, active, ongoing infection, or have undergone surgery
  • Infants who have received pharmacological analgesics or sedatives within 72 hours of the assessment
  • History of maternal abuse of controlled drugs and substances; blood collection that occurs beyond the 35th completed week (35 weeks + 6 days) GA
  • Small for GA defined as a birth weight at least 2 standard deviations below mean for GA
  • Higher order multiples (e.g. triplets)
  • Infants in a cot

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2018

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT01433588

Start Date

October 1 2014

End Date

May 1 2018

Last Update

July 17 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

BC Children's and Women's Health Centre

Vancouver, British Columbia, Canada, V6H3V4